Human cytomegalovirus (HCMV) remains a major clinical challenge in immunocompromised individuals and infants, yet no licensed vaccine exists
Viral latency, immune evasion, broad cell tropism and genomic complexity make vaccine development challenging and effective CMV vaccination likely requires coordinated humoral and cellular immunity
Evaxion’s AI-Immunology™ platform discovers and prioritizes novel B-cell and T-cell antigens, enabling data-driven design of multi-component CMV vaccine
Structure-guided antigen optimization, including pre-fusion stabilized gB and targeted T-cell epitope engraftment, enables the development of next-generation complementary CMV vaccines